GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement
RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene therapy for hemophilia. GeneVentiv plans to move the therapy into the clinic mid-2022. The technology, designated as GENV HEM offers a cure for all types of hemophilia patients with or without inhibitors to their missing clotting factors.
“There are promising gene therapies in development for hemophilia patients without inhibitors, but patients with inhibitors were being left behind. We’re changing that with a gene therapy for all hemophilia patients with or without inhibitors.”, said Damon Race, President and CEO of GeneVentiv Therapeutics.
GeneVentiv is a gene therapy company that develops and commercializes innovative therapies for people with life threatening, inherited disorders.